Fmr LLC Pds Biotechnology Corp Transaction History

Fmr LLC

$1.68 Trillion
Q2 2025

A detailed history of Fmr LLC transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Fmr LLC holds 1,025 shares of PDSB stock, worth $953. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,025

Previous 2,778 63.1%

Holding current value

$953

Previous $3,000 66.67%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$0.94 - $1.79 $1,647 - $3,137	-1,753 Reduced 63.1%	1,025 $1,000
Q1 2025 May 12, 2025	BUY	$1.18 - $1.8 $2,278 - $3,475	1,931 Added 227.98%	2,778 $3,000
Q4 2024 Feb 13, 2025	SELL	$1.63 - $4.11 $2,220 - $5,597	-1,362 Reduced 61.66%	847 $1,000
Q3 2024 Nov 13, 2024	SELL	$2.93 - $4.23 $653 - $943	-223 Reduced 9.17%	2,209 $8,000
Q2 2024 Aug 13, 2024	BUY	$2.55 - $4.02 $2,723 - $4,293	1,068 Added 78.3%	2,432 $7,000
Q1 2024 May 13, 2024	SELL	$3.85 - $6.59 $3,584 - $6,135	-931 Reduced 40.57%	1,364 $5,000
Q4 2023 Feb 13, 2024	BUY	$3.95 - $6.58 $3,077 - $5,125	779 Added 51.39%	2,295 $11,000
Q3 2023 Nov 13, 2023	SELL	$4.8 - $6.4 $1,737 - $2,316	-362 Reduced 19.28%	1,516 $7,000
Q2 2023 Aug 11, 2023	BUY	$5.03 - $9.9 $9,370 - $18,443	1,863 Added 12420.0%	1,878 $9,000
Q1 2023 May 11, 2023	SELL	$5.68 - $11.99 $11 - $23	-2 Reduced 11.76%	15 $0
Q4 2022 Feb 13, 2023	BUY	$3.28 - $13.2 $55 - $224	17 New	17 $0
Q3 2021 Nov 15, 2021	SELL	$9.33 - $17.08 $9 - $17	-1 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$4.35 - $12.86 $4 - $12	1 New	1 $0

Others Institutions Holding PDSB

# of Institutions

Shares Held

7.71M

Call Options Held

98.2K

Put Options Held

View Full List

About PDS Biotechnology Corp

Ticker PDSB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,458,700
Market Cap $26.5M
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...

More about PDSB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account